Baird Medical Investment (BDMD) vs Cerenome (CNSY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Baird Medical Investment (BDMD) has outperformed Cerenome (CNSY) over the past year, losing 93.6% versus a loss of 95.2%. Cerenome is the larger company by market cap ($6.2 million vs $5.1 million), about 1.2 times the size. Baird Medical Investment converts more of its revenue into profit, with a net margin of -121.0% versus -429.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDMD | CNSY |
|---|---|---|
| Share price | $0.0897 | $0.6301 |
| Market cap | $5.07M | $6.16M |
| 1-day change | -12.91% | -10.29% |
| YTD return | -93.40% | -95.06% |
| 1-year return | -93.64% | -95.24% |
| 5-year return | — | -99.89% |
| Forward P/E | 0.64 | — |
| EPS (TTM) | $-0.55 | $-3.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $22.54M | $5.21M |
| Revenue growth (YoY) | -39.15% | -10.49% |
| Net income (latest FY) | $-27.28M | $-22.39M |
| Gross margin | 83.79% | — |
| Operating margin | -113.73% | -293.46% |
| Net margin | -121.04% | -429.43% |
| 52-week high | $3.70 | $19.00 |
| 52-week low | $0.073 | $0.43 |
| Distance from 52-week high | -97.58% | -96.68% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +4359.31% | +4304.06% |
| Average volume | 16.31M | 804.18K |
| Shares outstanding | 56.52M | 9.78M |
| Employees | 146 | 28 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Baird Medical Investment is more profitable, keeping -121.0 cents of every revenue dollar as net income versus -429.4 cents for Cerenome.
- Cerenome grew revenue faster in its latest fiscal year (-10.49% vs -39.15%).
About Baird Medical Investment
BDMD stock →Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation.
Health Care · Medical/Dental Instruments · 146 employees
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Health Care · Medical/Dental Instruments · 28 employees
BDMD vs CNSY FAQ
Which is bigger, Baird Medical Investment or Cerenome?
Cerenome (CNSY) is larger, with a market capitalization of $6.16M compared with $5.07M for Baird Medical Investment (BDMD).
Which stock has performed better over the past year, BDMD or CNSY?
BDMD returned -93.64% over the past 12 months, compared with -95.24% for CNSY (price return, excluding dividends). Past performance does not predict future results.
Are Baird Medical Investment and Cerenome in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.